"Delta Waves provides primary care, clinical research services, comprehensive sleep medicine, and medical equipment in a pleasant, non-hospital environment. We are committed to delivering compassionate patient care in a personal, cost-effective timely manner."

During the past decade, Delta Waves, Inc. conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 11 clinical trials were completed, i.e. on average, 52.4% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 10 clinical trials were completed. i.e. 76.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Delta Waves, Inc." #1 sponsor was "Allergan" with 4 trials, followed by "Eli Lilly and Company" with 2 trials sponsored, "GlaxoSmithKline" with 2 trials sponsored, "Jazz Pharmaceuticals" with 2 trials sponsored and "Millennium Pharmaceuticals, Inc." with 2 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Delta Waves, Inc." #1 collaborator was "Bausch Health Americas, Inc." with 1 trials as a collaborator and "Takeda Development Center Americas, Inc." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Delta Waves, Inc." are "Sleep Apnea, Obstructive" (4 trials), "Attention Deficit Hyperactivity Disorder" (2 trials), "Episodic Migraine" (2 trials), "Idiopathic Hypersomnia" (2 trials) and "Insomnia" (2 trials). Many other conditions were trialed in "Delta Waves, Inc." in a lesser frequency.

Most popular intervention types in "Delta Waves, Inc." are "Drug" (18 trials) and "Device" (8 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Atogepant" (2 trials), "JZP-258" (2 trials), "Mirikizumab" (2 trials) and "Placebo-matching Ubrogepant" (2 trials). Other intervention names were less common.

The vast majority of trials in "Delta Waves, Inc." are 26 trials for "All" genders.

Currently, there are NaN active trials in "Delta Waves, Inc.". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in Delta Waves, Inc., undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Delta Waves, Inc., 2 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 7 trials that are defined as “Not Applicable".